EICHORCondition: Bladder Cancer · Sponsor: University of Kansas Medical Center
This is a phase II, single arm, Simon two-stage design, trial, enrolling patients with cisplatin ineligible MIBC and/or those patients who decline cisplatin based NAC. Assess rates of pathologic downstaging and quality of life in MIBC cisplatin-ineligible/declined patients when IVC is added to gemcitabine-carboplatin NAC.
This description comes directly from the study's public registry record.
KUCC Navigation · 913-588-3671 · kucc_navigation@kumc.edu
Faith Rahman · 913-588-2502 · frahman2@kumc.edu
Always discuss trial participation with your own doctor first.
| Holden Comprehensive Cancer Center - The University of Iowa | Iowa City, Iowa, United States | Not Yet Recruiting |
| The University of Kansas Cancer Center | Kansas City, Kansas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06493370